AbCellera Biologics Inc. Common Shares (ABCL)
NASDAQ: ABCL · Pharmaceutical Preparations · Vancouver, A1
Our rating: Cautious
Cautious reaffirmed at $12.46, moderate conviction, November 10, 2026.
Breaks if: The Cautious view is wrong if the next two quarterly filings (through mid-2027) each show free-cash-flow burn below $35M while year-over-year revenue growth holds above 80% — that combination would indicate the platform is converting partnerships to cash without proportional capital drag, making the current revenue multiple more defensible and warranting a move to Neutral. A stock that climbs and holds above $16.50 within twelve months would similarly indicate the market is seeing milestone conversion not visible in today's figures.
Key figures
| Market value | $3.2B |
|---|---|
| Revenue, last 12 months | $68M |
| Net income, last 12 months | −$148M |
| Free cash flow, last 12 months | −$33M |
| Price to earnings | n/a |
| Free cash flow yield | −1.0% |
| Dividend yield | 0.0% |
| Operating margin | −298.0% |
| Return on equity | −14.6% |
| Beta to the S&P 500 | 1.70 |
| Volatility, annualized | 77.9% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $11M | 18.8% | $-0.13 | $25M |
| June 30, 2026 | $4M | −76.3% | $-0.18 | $24M |
| March 31, 2026 | $8M | 96.3% | $-0.14 | −$37M |
| December 31, 2025 | $45M | 788.2% | $-0.03 | −$45M |
| September 30, 2025 | $9M | 37.6% | $-0.19 | −$62M |
| June 30, 2025 | $17M | 133.3% | $-0.12 | −$46M |
| March 31, 2025 | $4M | −57.5% | $-0.15 | −$22M |
| December 31, 2024 | $5M | −45.0% | $-0.11 | −$24M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.14B: Claude 5%, Gemini 5%, Mistral 8%
- Diluted earnings per share are above zero: Claude 8%, Gemini 3%, Mistral 5%
- Free cash flow for the quarter is above zero: Claude 55%, Gemini 70%, Mistral 60%
32 ledger entries and 10 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.